IQVIA leads $40m financing round for RWE and data analytics company Cota

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/jansucko)
(Image: iStock/jansucko)
The healthcare real-world evidence (RWE) and data analytics company Cota has completed a Series C financing round led by IQVIA.

EW Healthcare Partners, a growth equity firm, was also a “major” participant in the financing round, which raised $40m.

The funds will be used to advance Cota’s proprietary Cota Nodal Address (CNA) system, a precision disease classification system built on the company’s real-world data set, according to Cota.

The money will help scale its solutions across healthcare providers, payers and life sciences companies, according to the company.

Cota’s CNA-based Real World Evidence (RWE) offerings include Cota Research, Cota Payer Solution, Cota Provider Solution and Cota Life Sciences.

"We are excited to support Cota's unique oncology analytic environment and real-world data capabilities​," said Jon Resnick, president, real-world and analytics solutions, IQVIA, in a press release.

"We have been investing in applying data science to accelerate drug development, ensure patient access to innovative therapies, and make value and outcomes more transparent to align all healthcare stakeholders​,” said Resnick, adding that the investing in Cota is consistent with this vision.

As part of its participation, IQVIA has also gained a seat on Cota’s board of directors.

IQVIA is not providing any additional comment on the investment at this time.

Memorial Sloan Kettering Cancer Center also participated in the round, joining existing investors including Boston Millennia Partners, Horizon Blue Cross Blue Shield of New Jersey, Hackensack Meridian Health, and Atoc Holdings.

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us


View more